SALT LAKE CITY, Sept. 22, 2026 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq: CLNN) today announced that management will participate at the 5th Annual ROTH Healthcare Opportunities Conference and at the Lytham Partners Investor Conference Fall Event and host 1×1 investor meetings at both conferences.

5th Annual ROTH Healthcare Opportunities Conference
Date: September 29, 2026
Location: New York, NY
Format: 1×1 meetings
1×1 Meetings: Please contact your ROTH representative

Lytham Partners Investor Conference Fall Event
Date: September 29-30, 2026
Time of Presentation: 9:45 am ET
Location: Virtual
Format: Presentation and 1×1 meetings
1×1 Meetings: Please contact your Lytham representative
Webcast: link to webcast

A webcast of the presentation will be available on the “Events” section of the Clene website or using the webcast links above.

About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.

Investor Contact: Kevin Gardner, LifeSci Advisors; kgardner@lifesciadvisors.com; 617-283-2856
Media Contact: Caroline Wagner, FTP; CWagner@ftpadvocacy.com; (267) 294-6563 


Primary Logo

About The Author
Clene Inc.